61. Autoimmune hemolytic anemia
90 clinical trials,   72 drugs   (DrugBank: 23 drugs),   19 drug target genes,   147 drug target pathways

Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04398459
(ClinicalTrials.gov)
May 1, 202018/5/2020The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaA Phase II, Single-Center, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune HemolyticRefractory/Relapsed Autoimmune Hemolytic AnemiaDrug: IbrutinibInstitute of Hematology & Blood Diseases HospitalNULLRecruiting6 Years70 YearsAll18Phase 2China
2NCT03827603
(ClinicalTrials.gov)
February 21, 201724/1/2019Ibrutinib in Steroid Refractory Autoimmune Hemolytic AnemiaIbrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment ApproachAIHA - Warm Autoimmune Hemolytic AnemiaDrug: IbrutinibEugene NikitinNULLActive, not recruiting18 YearsN/AAll50Phase 2Russian Federation